Simeprevir and VX-135 Team Up in Phase II Hep C Trial

Share

Follow Us

Vertex’s VX-135 is being paired with Medivir and Janssen’s simeprevir in an all-oral Phase II Hepatitis C trial.

Phase II All-oral Study Of Simeprevir And VX-135 For The Treatment Of Hepatitis C

By News Staff | November 3rd 2012

Medivir AB has announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a drug-drug interaction study with simeprevir and VX-135 to support the planned initiation of a phase II proof-of-concept study in early 2013, pending discussions with regulatory authorities.

The phase II study is expected to evaluate safety, tolerability and viral cure rates using a 12-week combination of simeprevir and VX-135, with and without ribavirin. Janssen and Vertex will jointly fund development costs associated with the collaboration. There are no up-front or milestone payments associated with the agreement.

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.